about
Pharmacodynamic considerations for moderate and deep sedationCharacterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolamPharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureAlcohol withdrawal: what is the benzodiazepine of choice?Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitoneDifferential effect of isoniazid on triazolam oxidation and oxazepam conjugation.The geriatric population and psychiatric medicationInteraction of propoxyphene with diazepam, alprazolam and lorazepam.Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticusPharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.Understanding the pharmacokinetics of anxiolytic drugs.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies.Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics.Uptake, biotransformation and elimination of selected pharmaceuticals in a freshwater invertebrate measured using liquid chromatography tandem mass spectrometry.Hypnotics and anxiolytics.The influence of diflunisal on the pharmacokinetics of oxazepam.Lack of pharmacokinetic interaction between vinpocetine and oxazepam.Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.Effect of bioconcentration and trophic transfer on realized exposure to oxazepam in 2 predators, the dragonfly larvae (Aeshna grandis) and the Eurasian perch (Perca fluviatilis).Decreased systemic clearance of lorazepam in humans with spinal cord injury.Sedation and memory: studies with a histamine H-1 receptor antagonist.Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects.Quantitative structure-pharmacokinetic relationship modelling: apparent volume of distribution.Population Pharmacokinetic/ Pharmacodynamic Modelling of Auditory-Evoked Event-Related Potentials with Lorazepam.Antihistamine induced blood oxygenation level dependent response changes related to visual processes during sensori-motor performance.Severe withdrawal syndrome after substitution of a short-acting benzodiazepine for a long-acting benzodiazepine.The natural history of tolerance to the benzodiazepines
P2860
Q24613149-E503B924-3CB6-4464-A8FB-F4E4266FAB4EQ28277912-461A9C68-7F7F-49C7-A186-1EA5E8A73CA3Q34055606-54D0297F-69BD-47B4-973F-498863F2781FQ34336872-7A11DCF7-510F-4638-AF0D-B7781135C478Q34513258-AAB76B20-A723-44E1-B3BA-66BBB6A91168Q34514198-7C21CA6A-9BCB-4B6B-A595-09274A8A2749Q34543911-4D0B0020-878B-4F57-9A1D-F84E52F9F3A3Q34622454-C7123662-B701-42AF-8183-30598D9F33CAQ35742520-6AAAAC22-669B-43DB-A615-A25688B864F7Q35870770-A16592DF-6F67-4D0B-9646-2EFEBD039C6BQ37471079-D343E953-1F85-47C2-A593-445888824F30Q38075049-699FE574-7795-4FF2-9688-FDFAC9376474Q38152329-563B6B2D-9487-4140-9D75-C3F2005E9C8FQ38697044-A5A1ABA3-A111-42E7-AA27-7B951FD5353DQ40206942-CDF58E86-855F-4E41-8C10-ADD01E526333Q41097917-703D9814-FD13-4A7F-84C7-514B9EFB643BQ41811255-CD9B8E45-E750-41C5-A30D-AD75CDE2F0F0Q41966669-333B9521-E682-40EC-9D24-89582D50E6FFQ43201701-B0CAA0FA-C2FA-479B-8202-CDB9EBC5A30DQ43791592-7EDF5635-C31A-4D34-BF48-E6AEEF7DDEEAQ44036358-C8F27C39-61C8-48C2-9B91-9DF8595704AAQ46611434-A5B3AF15-0FE7-4648-90D5-625E7F9EAF9CQ46685696-620A6445-B864-46C3-876A-8B506954DE8DQ46886128-2B0B5078-54BA-4FD7-84BD-A503AD463AA2Q47622865-094CC0FF-7C08-4E5B-BEC6-249CFBED8BADQ47939712-97D9D194-5AC8-4803-B482-BB70D8492825Q48127960-B124D728-BFE4-4FE4-A9D2-AA2656AE65C0Q48922537-AA7A6933-8779-487A-9007-8215288E6BBCQ51821433-4B9EC217-E447-42C8-A572-B1E3A8855537Q55891551-08967D58-8B5A-43C2-A4D5-CFAE7DD6779F
P2860
description
1981 nî lūn-bûn
@nan
1981 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի մարտին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Clinical pharmacokinetics of oxazepam and lorazepam.
@ast
Clinical pharmacokinetics of oxazepam and lorazepam.
@en
Clinical pharmacokinetics of oxazepam and lorazepam.
@nl
type
label
Clinical pharmacokinetics of oxazepam and lorazepam.
@ast
Clinical pharmacokinetics of oxazepam and lorazepam.
@en
Clinical pharmacokinetics of oxazepam and lorazepam.
@nl
prefLabel
Clinical pharmacokinetics of oxazepam and lorazepam.
@ast
Clinical pharmacokinetics of oxazepam and lorazepam.
@en
Clinical pharmacokinetics of oxazepam and lorazepam.
@nl
P1476
Clinical pharmacokinetics of oxazepam and lorazepam.
@en
P2093
Greenblatt DJ
P304
P356
10.2165/00003088-198106020-00001
P577
1981-03-01T00:00:00Z
P6179
1002487364